Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Executive Summary

• Eupraxia Pharmaceuticals reported Q4 2025 net loss of $16.7 M, but cash on hand rose to $80.5 M driven by a $63.2 M public offering completed on Feb 20 2026.
• The company disclosed positive clinical readouts from the RESOLVE trial in eosinophilic esophagitis (EoE), including 52‑week follow‑up data and near‑complete biopsy improvement.
• Management indicated that existing cash, proceeds from the offering, and anticipated warrant exercises are expected to fund operations into the second half of 2028.

Key Details

• Financing: Closed a public offering of 7,607,145 common shares at $7.00 per share; gross proceeds ≈ $63.2 M. Included full exercise of underwriters’ option for 1,178,571 additional shares and issuance of 1,428,571 pre‑funded warrants at $6.99999 each.
• Cash Position: $80.5 M as of Dec 31 2025 (up from $33.1 M at end of Q4 2024).
• Share Count: 51,939,206 common shares and 8,355,638 preferred shares outstanding as of Dec 31 2025.
• Net Loss: $16.7 M for Q4 2025 vs. $7.5 M for Q4 2024; increase driven by higher R&D spend on EP‑104GI and higher G&A expenses.
• Clinical Milestones – RESOLVE Trial (EoE):
• Nov 13 2025: 52‑week follow‑up data showed consistent results post‑dosing with EP‑104GI.
• Jan 8 2026: Positive tissue health data demonstrated near‑complete improvement on biopsy.
• Runway Outlook: Existing cash plus offering proceeds and expected in‑the‑money warrant exercises projected to fund the company through H2 2028.
• Tariff Monitoring: Management is assessing potential impacts of U.S./Canadian tariff changes on supply chain and costs; no material effect identified to date.

Notable Quotes

“2025 was a pivotal year for Eupraxia… we achieved significant clinical milestones… and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth.” – James Helliwell, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the release.